Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Jennifer L. Taylor-Cousar

TitleAffiliate - NJH
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-MED

    Collapse Research 
    Collapse research activities and funding
    K23HL103801     (TAYLOR-COUSAR, JENNIFER L)Jun 15, 2011 - Nov 30, 2016
    NIH
    Use of Phosphodiesterase Inhibitors to Evaluate the Pathobiology of CF
    Role: Principal Investigator

    F32HL082207     (TAYLOR-COUSAR, JENNIFER L)Jul 19, 2005 - Jul 18, 2007
    NIH
    Genetic Modifiers in CF: Role of ABH polymorphisms
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Montemayor K, Kazmerski TM, Riekert KA, Psoter KJ, Jain R, Taylor-Cousar JL, Aitken ML, Boyle RL, Patel S, West NE. Clinician attitudes and practices on pregnancy planning and care in cystic fibrosis. J Cyst Fibros. 2022 Jul 21. PMID: 35871973.
      View in: PubMed
    2. Jain R, Magaret A, Vu PT, VanDalfsen JM, Keller A, Wilson A, Putman MS, Mayer-Hamblett N, Esther CR, Taylor-Cousar JL. Prospectively evaluating maternal and fetal outcomes in the era of CFTR modulators: the MAYFLOWERS observational clinical trial study design. BMJ Open Respir Res. 2022 06; 9(1). PMID: 35710144.
      View in: PubMed
    3. Beswick DM, Humphries SM, Miller JE, Balkissoon CD, Khatiwada A, Vladar EK, Ramakrishnan VR, Lynch DA, Taylor-Cousar JL. Objective and patient-based measures of chronic rhinosinusitis in people with cystic fibrosis treated with highly effective modulator therapy. Int Forum Allergy Rhinol. 2022 May 20. PMID: 35595546.
      View in: PubMed
    4. Izquierdo ME, Marion CR, Moore WC, Raraigh KS, Taylor-Cousar JL, Cutting GR, Ampleford E, Hawkins GA, Zein J, Castro M, Denlinger LC, Erzurum SC, Fahy JV, Israel E, Jarjour NN, Mauger D, Levy BD, Wenzel SE, Woodruff P, Bleecker ER, Meyers DA, Ortega VE. DNA sequencing analysis of cystic fibrosis transmembrane conductance regulator gene identifies cystic fibrosis-associated variants in the Severe Asthma Research Program. Pediatr Pulmonol. 2022 07; 57(7):1782-1788. PMID: 35451201.
      View in: PubMed
    5. Caceres SM, Sanders LA, Rysavy NM, Poch KR, Jones CR, Pickard K, Fingerlin TE, Marcus RA, Malcolm KC, Taylor-Cousar JL, Nichols DP, Nick JA, Strand M, Saavedra MT. Blood mRNA biomarkers distinguish variable systemic and sputum inflammation at treatment initiation of inhaled antibiotics in cystic fibrosis: A prospective non-randomized trial. PLoS One. 2022; 17(5):e0267592. PMID: 35511761.
      View in: PubMed
    6. Kramer-Golinkoff E, Camacho A, Kramer L, Taylor-Cousar JL. A survey: Understanding the health and perspectives of people with CF not benefiting from CFTR modulators. Pediatr Pulmonol. 2022 05; 57(5):1253-1261. PMID: 35170259.
      View in: PubMed
    7. Kazmerski TM, Jain R, Lee M, Taylor-Cousar JL. Parenthood impacts short-term health outcomes in people with cystic fibrosis. J Cyst Fibros. 2022 Jul; 21(4):662-668. PMID: 35181269.
      View in: PubMed
    8. Stransky OM, Pam M, Ladores SL, Birru Talabi M, Borrero S, Godfrey EM, Roe AH, Sawicki GS, Zuckerwise LC, Mody S, Mentch L, Deal A, O'Leary R, Taylor-Cousar JL, Jain R, Kazmerski TM. Engaging Stakeholders in the Development of a Reproductive Goals Decision AID for Women with Cystic Fibrosis. J Patient Exp. 2022; 9:23743735221077527. PMID: 35128042.
      View in: PubMed
    9. Beswick DM, Humphries SM, Balkissoon CD, Strand M, E Miller J, Khatiwada A, Vladar EK, Lynch DA, Taylor-Cousar JL. Olfactory dysfunction in people with cystic fibrosis with at least one copy of F508del. Int Forum Allergy Rhinol. 2022 07; 12(7):963-966. PMID: 34908251.
      View in: PubMed
    10. Beswick DM, Humphries SM, Balkissoon CD, Strand M, Vladar EK, Lynch DA, Taylor-Cousar JL. Impact of Cystic Fibrosis Transmembrane Conductance Regulator Therapy on Chronic Rhinosinusitis and Health Status: Deep Learning CT Analysis and Patient-reported Outcomes. Ann Am Thorac Soc. 2022 01; 19(1):12-19. PMID: 34436985.
      View in: PubMed
    11. Sriningsih AP, Lung NP, Sulistyo F, Aronson SA, Aronson RK, Taylor-Cousar JL. EVALUATING THE EFFICACY OF HUMAN BRONCHIECTASISBASED ANTIBIOTIC THERAPY IN THE TREATMENT OF ORANGUTAN RESPIRATORY DISEASE SYNDROME. J Zoo Wildl Med. 2021 Dec; 52(4):1205-1216. PMID: 34998290.
      View in: PubMed
    12. Barry PJ, Taylor-Cousar JL. Triple combination cystic fibrosis transmembrane conductance regulator modulator therapy in the real world - opportunities and challenges. Curr Opin Pulm Med. 2021 11 01; 27(6):554-566. PMID: 34420018.
      View in: PubMed
    13. West NE, Kazmerski TM, Taylor-Cousar JL, Tangpricha V, Pearson K, Aitken ML, Jain R. Optimizing sexual and reproductive health across the lifespan in people with cystic fibrosis. Pediatr Pulmonol. 2022 02; 57 Suppl 1:S89-S100. PMID: 34570960.
      View in: PubMed
    14. Beswick DM, Humphries SM, Balkissoon CD, Strand M, Vladar EK, Ramakrishnan VR, Taylor-Cousar JL. Olfactory dysfunction in cystic fibrosis: Impact of CFTR modulator therapy. J Cyst Fibros. 2022 03; 21(2):e141-e147. PMID: 34598881.
      View in: PubMed
    15. Elborn JS, Konstan MW, Taylor-Cousar JL, Fajac I, Horsley A, Sutharsan S, Aaron SD, Daines CL, Uluer A, Downey DG, Lucidi VV, Ahuja S, Springman E, Mershon J, Grosswald R, Rowe SM. Empire-CF study: A phase 2 clinical trial of leukotriene A4 hydrolase inhibitor acebilustat in adult subjects with cystic fibrosis. J Cyst Fibros. 2021 11; 20(6):1026-1034. PMID: 34538755.
      View in: PubMed
    16. Jain R, Kazmerski TM, Aitken ML, West N, Wilson A, Bozkanat KM, Montemayor K, von Berg K, Sjoberg J, Poranski M, Taylor-Cousar JL. Challenges Faced by Women with Cystic Fibrosis. Clin Chest Med. 2021 09; 42(3):517-530. PMID: 34353456.
      View in: PubMed
    17. Barry PJ, Mall MA, Álvarez A, Colombo C, de Winter-de Groot KM, Fajac I, McBennett KA, McKone EF, Ramsey BW, Sutharsan S, Taylor-Cousar JL, Tullis E, Ahluwalia N, Jun LS, Moskowitz SM, Prieto-Centurion V, Tian S, Waltz D, Xuan F, Zhang Y, Rowe SM, Polineni D. Triple Therapy for Cystic Fibrosis Phe508del-Gating and -Residual Function Genotypes. N Engl J Med. 2021 08 26; 385(9):815-825. PMID: 34437784.
      View in: PubMed
    18. Jain R, Kazmerski TM, Zuckerwise LC, West NE, Montemayor K, Aitken ML, Cheng E, Roe AH, Wilson A, Mann C, Ladores S, Sjoberg J, Poranski M, Taylor-Cousar JL. Pregnancy in cystic fibrosis: Review of the literature and expert recommendations. J Cyst Fibros. 2022 05; 21(3):387-395. PMID: 34456158.
      View in: PubMed
    19. Derichs N, Taylor-Cousar JL, Davies JC, Fajac I, Tullis E, Nazareth D, Downey DG, Rosenbluth D, Malfroot A, Saunders C, Jensen R, Solomon GM, Vermeulen F, Kaiser A, Willmann S, Saleh S, Droebner K, Sandner P, Bear CE, Hoffmann A, Ratjen F, Rowe SM. Riociguat for the treatment of Phe508del homozygous adults with cystic fibrosis. J Cyst Fibros. 2021 11; 20(6):1018-1025. PMID: 34419414.
      View in: PubMed
    20. Kazmerski TM, West NE, Jain R, Uluer A, Georgiopoulos AM, Aitken ML, Taylor-Cousar JL. Family-building and parenting considerations for people with cystic fibrosis. Pediatr Pulmonol. 2022 02; 57 Suppl 1:S75-S88. PMID: 34407321.
      View in: PubMed
    21. Shteinberg M, Taylor-Cousar JL, Durieu I, Cohen-Cymberknoh M. Fertility and Pregnancy in Cystic Fibrosis. Chest. 2021 12; 160(6):2051-2060. PMID: 34284004.
      View in: PubMed
    22. Zemanick ET, Taylor-Cousar JL, Davies J, Gibson RL, Mall MA, McKone EF, McNally P, Ramsey BW, Rayment JH, Rowe SM, Tullis E, Ahluwalia N, Chu C, Ho T, Moskowitz SM, Noel S, Tian S, Waltz D, Weinstock TG, Xuan F, Wainwright CE, McColley SA. A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele. Am J Respir Crit Care Med. 2021 06 15; 203(12):1522-1532. PMID: 33734030.
      View in: PubMed
    23. Poore TS, Taylor-Cousar JL, Zemanick ET. Cardiovascular complications in cystic fibrosis: A review of the literature. J Cyst Fibros. 2022 01; 21(1):18-25. PMID: 34140249.
      View in: PubMed
    24. Aronson RK, Sriningsih AP, Sulistyo F, Taylor-Cousar JL, Aronson SA, South A, Nutter F, Lung NP. USE OF COMPUTED TOMOGRAPHY (CT) TO DETERMINE THE SENSITIVITY OF CLINICAL SIGNS AS A DIAGNOSTIC TOOL FOR RESPIRATORY DISEASE IN BORNEAN ORANGUTANS (PONGO PYGMAEUS). J Zoo Wildl Med. 2021 Jun; 52(2):470-478. PMID: 34130389.
      View in: PubMed
    25. Jain R, Taylor-Cousar JL. Fertility, Pregnancy and Lactation Considerations for Women with CF in the CFTR Modulator Era. J Pers Med. 2021 May 15; 11(5). PMID: 34063507.
      View in: PubMed
    26. Guimbellot JS, Taylor-Cousar JL. Combination CFTR modulator therapy in children and adults with cystic fibrosis. Lancet Respir Med. 2021 07; 9(7):677-679. PMID: 33965001.
      View in: PubMed
    27. Taylor-Cousar JL, Jain R. Maternal and fetal outcomes following elexacaftor-tezacaftor-ivacaftor use during pregnancy and lactation. J Cyst Fibros. 2021 05; 20(3):402-406. PMID: 33762125.
      View in: PubMed
    28. Middleton PG, Taylor-Cousar JL. Development of elexacaftor - tezacaftor - ivacaftor: Highly effective CFTR modulation for the majority of people with Cystic Fibrosis. Expert Rev Respir Med. 2021 06; 15(6):723-735. PMID: 33249928.
      View in: PubMed
    29. Griese M, Costa S, Linnemann RW, Mall MA, McKone EF, Polineni D, Quon BS, Ringshausen FC, Taylor-Cousar JL, Withers NJ, Moskowitz SM, Daines CL. Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial. Am J Respir Crit Care Med. 2021 02 01; 203(3):381-385. PMID: 32969708.
      View in: PubMed
    30. Ramos KJ, Pilewski JM, Taylor-Cousar JL. Challenges in the use of highly effective modulator treatment for cystic fibrosis. J Cyst Fibros. 2021 05; 20(3):381-387. PMID: 33531206.
      View in: PubMed
    31. Khan FN, Tangpricha V, Hughan KS, Jain R, Ladores SL, Taylor-Cousar JL, West NE, Montemayor K, Sawicki GS, Uluer A, Aitken ML, Shnorhavorian M, Bray LA, Kvam C, Stalvey M, Kazmerski TM. Men's health in the modern era of cystic fibrosis. J Cyst Fibros. 2021 11; 20(6):e121-e123. PMID: 33376059.
      View in: PubMed
    32. Taylor-Cousar JL, Maier L, Downey GP, Wechsler ME. Restarting Respiratory Clinical Research in the Era of the Coronavirus Disease 2019 Pandemic. Chest. 2021 03; 159(3):1173-1181. PMID: 33197402.
      View in: PubMed
    33. Beswick DM, Humphries SM, Balkissoon CD, Vladar EK, Ramakrishnan VR, Lynch DA, Taylor-Cousar JL. Machine learning evaluates improvement in sinus computed tomography opacification with CFTR modulator therapy. Int Forum Allergy Rhinol. 2021 05; 11(5):953-954. PMID: 33140564.
      View in: PubMed
    34. McCoy KS, Heijerman H, Taylor-Cousar JL, Waltz D, Sosnay PR, Ramsey BW, Rowe S, Welter J. Transparency and diversity in cystic fibrosis research - Authors' reply. Lancet. 2020 08 29; 396(10251):602. PMID: 32861305.
      View in: PubMed
    35. Taylor-Cousar JL. CFTR Modulators: Impact on Fertility, Pregnancy, and Lactation in Women with Cystic Fibrosis. J Clin Med. 2020 Aug 21; 9(9). PMID: 32825766.
      View in: PubMed
    36. Taylor-Cousar JL, Jain R, Kazmerski TM, Aitken ML, West NE, Wilson A, Middleton PG, Nash EF. Concerns regarding the safety of azithromycin in pregnancy - relevance for women with cystic fibrosis. J Cyst Fibros. 2021 05; 20(3):395-396. PMID: 32800485.
      View in: PubMed
    37. Mayer-Hamblett N, van Koningsbruggen-Rietschel S, Nichols DP, VanDevanter DR, Davies JC, Lee T, Durmowicz AG, Ratjen F, Konstan MW, Pearson K, Bell SC, Clancy JP, Taylor-Cousar JL, De Boeck K, Donaldson SH, Downey DG, Flume PA, Drevinek P, Goss CH, Fajac I, Magaret AS, Quon BS, Singleton SM, VanDalfsen JM, Retsch-Bogart GZ. Building global development strategies for cf therapeutics during a transitional cftr modulator era. J Cyst Fibros. 2020 09; 19(5):677-687. PMID: 32522463.
      View in: PubMed
    38. Shteinberg M, Taylor-Cousar JL. Impact of CFTR modulator use on outcomes in people with severe cystic fibrosis lung disease. Eur Respir Rev. 2020 Mar 31; 29(155). PMID: 32198216.
      View in: PubMed
    39. Langawi MA, Byrnes C, Davies JC, Hamouda S, Kabra M, Rached SZ, Sands D, Shteinberg M, Taylor-Cousar J, Tullis E, Wainwright C. 'Go for it, dream big, work hard and persist': A message to the next generation of CF leaders in recognition of International Women's Day 2020. J Cyst Fibros. 2020 03; 19(2):184-193. PMID: 32156627.
      View in: PubMed
    40. Nash EF, Middleton PG, Taylor-Cousar JL. Outcomes of pregnancy in women with cystic fibrosis (CF) taking CFTR modulators - an international survey. J Cyst Fibros. 2020 07; 19(4):521-526. PMID: 32151568.
      View in: PubMed
    41. Godfrey EM, Mody S, Schwartz MR, Heltshe SL, Taylor-Cousar JL, Jain R, Sufian S, Josephy T, Aitken ML. Contraceptive use among women with cystic fibrosis: A pilot study linking reproductive health questions to the Cystic Fibrosis Foundation National Patient Registry. Contraception. 2020 06; 101(6):420-426. PMID: 32109430.
      View in: PubMed
    42. Taylor-Cousar JL, Evans TA, Cutting GR, Sharma N. Potentially lethal cystic fibrosis gene variant in the orangutan. Am J Primatol. 2021 12; 83(12):e23097. PMID: 31967360.
      View in: PubMed
    43. Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, Mall MA, Welter JJ, Ramsey BW, McKee CM, Marigowda G, Moskowitz SM, Waltz D, Sosnay PR, Simard C, Ahluwalia N, Xuan F, Zhang Y, Taylor-Cousar JL, McCoy KS. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet. 2019 11 23; 394(10212):1940-1948. PMID: 31679946.
      View in: PubMed
    44. Middleton PG, Mall MA, Drevínek P, Lands LC, McKone EF, Polineni D, Ramsey BW, Taylor-Cousar JL, Tullis E, Vermeulen F, Marigowda G, McKee CM, Moskowitz SM, Nair N, Savage J, Simard C, Tian S, Waltz D, Xuan F, Rowe SM, Jain R. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. N Engl J Med. 2019 11 07; 381(19):1809-1819. PMID: 31697873.
      View in: PubMed
    45. Downey DG, Taylor-Cousar J. Letter to the editor: Challenges and opportunities in the development of future CFTR modulator options for people with CF. J Cyst Fibros. 2020 01; 19(1):e1-e2. PMID: 31672556.
      View in: PubMed
    46. Somayaji R, Russell R, Cogen JD, Goss CH, Nick SE, Saavedra MT, Taylor-Cousar JL, Nick JA, Nichols DP. Oral Azithromycin Use and the Recovery of Lung Function from Pulmonary Exacerbations Treated with Intravenous Tobramycin or Colistimethate in Adults with Cystic Fibrosis. Ann Am Thorac Soc. 2019 07; 16(7):853-860. PMID: 30840835.
      View in: PubMed
    47. Taylor-Cousar JL, Mall MA, Ramsey BW, McKone EF, Tullis E, Marigowda G, McKee CM, Waltz D, Moskowitz SM, Savage J, Xuan F, Rowe SM. Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles. ERJ Open Res. 2019 Apr; 5(2). PMID: 31218221.
      View in: PubMed
    48. Liou TG, Adler FR, Argel N, Asfour F, Brown PS, Chatfield BA, Daines CL, Durham D, Francis JA, Glover B, Heynekamp T, Hoidal JR, Jensen JL, Keogh R, Kopecky CM, Lechtzin N, Li Y, Lysinger J, Molina O, Nakamura C, Packer KA, Poch KR, Quittner AL, Radford P, Redway AJ, Sagel SD, Sprandel S, Taylor-Cousar JL, Vroom JB, Yoshikawa R, Clancy JP, Elborn JS, Olivier KN, Cox DR. Prospective multicenter randomized patient recruitment and sample collection to enable future measurements of sputum biomarkers of inflammation in an observational study of cystic fibrosis. BMC Med Res Methodol. 2019 04 26; 19(1):88. PMID: 31027503.
      View in: PubMed
    49. Lommatzsch ST, Taylor-Cousar JL. The combination of tezacaftor and ivacaftor in the treatment of patients with cystic fibrosis: clinical evidence and future prospects in cystic fibrosis therapy. Ther Adv Respir Dis. 2019 Jan-Dec; 13:1753466619844424. PMID: 31027466.
      View in: PubMed
    50. Pohl K, Nichols DP, Taylor-Cousar JL, Saavedra MT, Strand MJ, Nick JA, Bratcher PE. Corticosteroid use and increased CXCR2 levels on leukocytes are associated with lumacaftor/ivacaftor discontinuation in cystic fibrosis patients homozygous for the F508del CFTR mutation. PLoS One. 2018; 13(12):e0209026. PMID: 30540818.
      View in: PubMed
    51. Bratcher PE, Hunt KC, Pickard K, Taylor-Cousar JL. Positive clinical response to ivacaftor treatment in an individual with the CFTR genotype F508del/V456A. J Cyst Fibros. 2019 03; 18(2):e9-e10. PMID: 30348612.
      View in: PubMed
    52. Keating D, Marigowda G, Burr L, Daines C, Mall MA, McKone EF, Ramsey BW, Rowe SM, Sass LA, Tullis E, McKee CM, Moskowitz SM, Robertson S, Savage J, Simard C, Van Goor F, Waltz D, Xuan F, Young T, Taylor-Cousar JL. VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. N Engl J Med. 2018 10 25; 379(17):1612-1620. PMID: 30334692.
      View in: PubMed
    53. Davies JC, Moskowitz SM, Brown C, Horsley A, Mall MA, McKone EF, Plant BJ, Prais D, Ramsey BW, Taylor-Cousar JL, Tullis E, Uluer A, McKee CM, Robertson S, Shilling RA, Simard C, Van Goor F, Waltz D, Xuan F, Young T, Rowe SM. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. N Engl J Med. 2018 10 25; 379(17):1599-1611. PMID: 30334693.
      View in: PubMed
    54. Saavedra MT, Quon BS, Faino A, Caceres SM, Poch KR, Sanders LA, Malcolm KC, Nichols DP, Sagel SD, Taylor-Cousar JL, Leach SM, Strand M, Nick JA. Whole Blood Gene Expression Profiling Predicts Severe Morbidity and Mortality in Cystic Fibrosis: A 5-Year Follow-Up Study. Ann Am Thorac Soc. 2018 05; 15(5):589-598. PMID: 29425066.
      View in: PubMed
    55. Heltshe SL, Taylor-Cousar JL. Let's talk about sex: Behaviors, experience and health care utilization in young women with CF. J Cyst Fibros. 2018 01; 17(1):5-6. PMID: 29191659.
      View in: PubMed
    56. Taylor-Cousar JL, Jain M, Barto TL, Haddad T, Atkinson J, Tian S, Tang R, Marigowda G, Waltz D, Pilewski J. Lumacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease homozygous for F508del-CFTR. J Cyst Fibros. 2018 03; 17(2):228-235. PMID: 29126871.
      View in: PubMed
    57. Taylor-Cousar JL, Munck A, McKone EF, van der Ent CK, Moeller A, Simard C, Wang LT, Ingenito EP, McKee C, Lu Y, Lekstrom-Himes J, Elborn JS. Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del. N Engl J Med. 2017 11 23; 377(21):2013-2023. PMID: 29099344.
      View in: PubMed
    58. Donaldson SH, Solomon GM, Zeitlin PL, Flume PA, Casey A, McCoy K, Zemanick ET, Mandagere A, Troha JM, Shoemaker SA, Chmiel JF, Taylor-Cousar JL. Pharmacokinetics and safety of cavosonstat (N91115) in healthy and cystic fibrosis adults homozygous for F508DEL-CFTR. J Cyst Fibros. 2017 May; 16(3):371-379. PMID: 28209466.
      View in: PubMed
    59. Heltshe SL, Godfrey EM, Josephy T, Aitken ML, Taylor-Cousar JL. Pregnancy among cystic fibrosis women in the era of CFTR modulators. J Cyst Fibros. 2017 Nov; 16(6):687-694. PMID: 28190780.
      View in: PubMed
    60. Nichols DP, Happoldt CL, Bratcher PE, Caceres SM, Chmiel JF, Malcolm KC, Saavedra MT, Saiman L, Taylor-Cousar JL, Nick JA. Impact of azithromycin on the clinical and antimicrobial effectiveness of tobramycin in the treatment of cystic fibrosis. J Cyst Fibros. 2017 May; 16(3):358-366. PMID: 28025037.
      View in: PubMed
    61. Taylor-Cousar JL, Janssen JS, Wilson A, Clair CG, Pickard KM, Jones MC, Brayshaw SJ, Chacon CS, Barboa CM, Sontag MK, Accurso FJ, Nichols DP, Saavedra MT, Nick JA. Glucose >200?mg/dL during Continuous Glucose Monitoring Identifies Adult Patients at Risk for Development of Cystic Fibrosis Related Diabetes. J Diabetes Res. 2016; 2016:1527932. PMID: 27999822.
      View in: PubMed
    62. Nick JA, Caceres SM, Kret JE, Poch KR, Strand M, Faino AV, Nichols DP, Saavedra MT, Taylor-Cousar JL, Geraci MW, Burnham EL, Fessler MB, Suratt BT, Abraham E, Moss M, Malcolm KC. Extremes of Interferon-Stimulated Gene Expression Associate with Worse Outcomes in the Acute Respiratory Distress Syndrome. PLoS One. 2016; 11(9):e0162490. PMID: 27606687.
      View in: PubMed
    63. Stringer E, Cossaboon C, Han S, Taylor-Cousar JL. SINUSITIS, BRONCHIECTASIS, AND FLATUS IN A SUMATRAN ORANGUTAN (PONGO ABELII): COULD THIS BE CYSTIC FIBROSIS? J Zoo Wildl Med. 2016 Mar; 47(1):347-50. PMID: 27010300.
      View in: PubMed
    64. Kuk K, Taylor-Cousar JL. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects. Ther Adv Respir Dis. 2015 Dec; 9(6):313-26. PMID: 26416827.
      View in: PubMed
    65. Taylor-Cousar J, Niknian M, Gilmartin G, Pilewski JM. Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United States. J Cyst Fibros. 2016 Jan; 15(1):116-22. PMID: 25682022.
      View in: PubMed
    66. Taylor-Cousar JL, Wiley C, Felton LA, St Clair C, Jones M, Curran-Everett D, Poch K, Nichols DP, Solomon GM, Saavedra MT, Accurso FJ, Nick JA. Pharmacokinetics and tolerability of oral sildenafil in adults with cystic fibrosis lung disease. J Cyst Fibros. 2015 Mar; 14(2):228-36. PMID: 25466700.
      View in: PubMed
    67. Ferril GR, Nick JA, Getz AE, Barham HP, Saavedra MT, Taylor-Cousar JL, Nichols DP, Curran-Everett D, Kingdom TT, Ramakrishnan VR. Comparison of radiographic and clinical characteristics of low-risk and high-risk cystic fibrosis genotypes. Int Forum Allergy Rhinol. 2014 Nov; 4(11):915-20. PMID: 25224556.
      View in: PubMed
    68. Caceres SM, Malcolm KC, Taylor-Cousar JL, Nichols DP, Saavedra MT, Bratton DL, Moskowitz SM, Burns JL, Nick JA. Enhanced in vitro formation and antibiotic resistance of nonattached Pseudomonas aeruginosa aggregates through incorporation of neutrophil products. Antimicrob Agents Chemother. 2014 Nov; 58(11):6851-60. PMID: 25182651.
      View in: PubMed
    69. Nick JA, Moskowitz SM, Chmiel JF, Forssén AV, Kim SH, Saavedra MT, Saiman L, Taylor-Cousar JL, Nichols DP. Azithromycin may antagonize inhaled tobramycin when targeting Pseudomonas aeruginosa in cystic fibrosis. Ann Am Thorac Soc. 2014 Mar; 11(3):342-50. PMID: 24476418.
      View in: PubMed
    70. Nick JA, Sanders LA, Ickes B, Briones NJ, Caceres SM, Malcolm KC, Brayshaw SJ, Chacon CS, Barboa CM, Jones MC, St Clair C, Taylor-Cousar JL, Nichols DP, Sagel SD, Strand M, Saavedra MT. Blood mRNA biomarkers for detection of treatment response in acute pulmonary exacerbations of cystic fibrosis. Thorax. 2013 Oct; 68(10):929-37. PMID: 23783371.
      View in: PubMed
    71. Malcolm KC, Nichols EM, Caceres SM, Kret JE, Martiniano SL, Sagel SD, Chan ED, Caverly L, Solomon GM, Reynolds P, Bratton DL, Taylor-Cousar JL, Nichols DP, Saavedra MT, Nick JA. Mycobacterium abscessus induces a limited pattern of neutrophil activation that promotes pathogen survival. PLoS One. 2013; 8(2):e57402. PMID: 23451220.
      View in: PubMed
    72. Nichols DP, Caceres S, Caverly L, Fratelli C, Kim SH, Malcolm K, Poch KR, Saavedra M, Solomon G, Taylor-Cousar J, Moskowitz S, Nick JA. Effects of azithromycin in Pseudomonas aeruginosa burn wound infection. J Surg Res. 2013 Aug; 183(2):767-76. PMID: 23478086.
      View in: PubMed
    73. Rasouli N, Seggelke S, Gibbs J, Hawkins RM, Casciano ML, Cohlmia E, Taylor-Cousar J, Wang C, Pereira R, Hsia E, Draznin B. Cystic fibrosis-related diabetes in adults: inpatient management of 121 patients during 410 admissions. J Diabetes Sci Technol. 2012 Sep 01; 6(5):1038-44. PMID: 23063029.
      View in: PubMed
    74. Young RL, Malcolm KC, Kret JE, Caceres SM, Poch KR, Nichols DP, Taylor-Cousar JL, Saavedra MT, Randell SH, Vasil ML, Burns JL, Moskowitz SM, Nick JA. Neutrophil extracellular trap (NET)-mediated killing of Pseudomonas aeruginosa: evidence of acquired resistance within the CF airway, independent of CFTR. PLoS One. 2011; 6(9):e23637. PMID: 21909403.
      View in: PubMed
    75. Taylor-Cousar JL, Von Kessel KA, Young R, Nichols DP. Potential of anti-inflammatory treatment for cystic fibrosis lung disease. J Inflamm Res. 2010; 3:61-74. PMID: 22096358.
      View in: PubMed
    76. Nick JA, Chacon CS, Brayshaw SJ, Jones MC, Barboa CM, St Clair CG, Young RL, Nichols DP, Janssen JS, Huitt GA, Iseman MD, Daley CL, Taylor-Cousar JL, Accurso FJ, Saavedra MT, Sontag MK. Effects of gender and age at diagnosis on disease progression in long-term survivors of cystic fibrosis. Am J Respir Crit Care Med. 2010 Sep 01; 182(5):614-26. PMID: 20448091.
      View in: PubMed
    77. Taylor-Cousar JL. Hypoventilation in cystic fibrosis. Semin Respir Crit Care Med. 2009 Jun; 30(3):293-302. PMID: 19452389.
      View in: PubMed
    78. Taylor-Cousar JL, Zariwala MA, Burch LH, Pace RG, Drumm ML, Calloway H, Fan H, Weston BW, Wright FA, Knowles MR. Histo-blood group gene polymorphisms as potential genetic modifiers of infection and cystic fibrosis lung disease severity. PLoS One. 2009; 4(1):e4270. PMID: 19169360.
      View in: PubMed
    79. Ornatowski W, Poschet JF, Perkett E, Taylor-Cousar JL, Deretic V. Elevated furin levels in human cystic fibrosis cells result in hypersusceptibility to exotoxin A-induced cytotoxicity. J Clin Invest. 2007 Nov; 117(11):3489-97. PMID: 17948127.
      View in: PubMed
    80. Poschet JF, Timmins GS, Taylor-Cousar JL, Ornatowski W, Fazio J, Perkett E, Wilson KR, Yu HD, de Jonge HR, Deretic V. Pharmacological modulation of cGMP levels by phosphodiesterase 5 inhibitors as a therapeutic strategy for treatment of respiratory pathology in cystic fibrosis. Am J Physiol Lung Cell Mol Physiol. 2007 Sep; 293(3):L712-9. PMID: 17586695.
      View in: PubMed
    Taylor-Cousar's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description

    Copyright © 2022 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)